Ariel Avilion
Scientific Associate Director at Bristol Myers Squibb | Translational Medicine | Clinical Oncology Biomarker Development | Cell Therapy & Immuno-Oncology | Global Clinical Trials
- Role
- Scientific Associate Director Translational Research Cellular Therapy at Bristol Myers Squibb
- Location
- Seattle, WA, US
- LinkedIn followers
- 500 followers
About Ariel Avilion
Dynamic and results-driven research leader with expertise in translational oncology and biomarker strategy for both early- and late-stage clinical trials. Specializes in designing and implementing cutting-edge biomarker discovery, assay validation, and clinical protocol development, with a focus on cellular therapies, including CAR-T and immuno-oncology approaches. Proven track record of successful regulatory submissions, health authority interactions, and cross-disciplinary team leadership. Demonstrates a commitment to advancing personalized medicine and improving patient outcomes through innovative therapeutic strategies.Key Expertise:• Translational Oncology & Personalized Medicine• Cellular Therapy (CAR-T) & Immuno-Oncology• Small & Large Molecule Therapeutics• Cross-functional Team Leadership & Strategic Program Management• Global Clinical Trials (Phase Regulatory Submissions and Health Authority Interactions• Biomarker Discovery & Assay Development • Clinical Protocol & Lab Manual Development• Clinical Sample Management & CRO OversightMy working style is probably best defined by the places I have lived. I like the collaboration and communal spirit that Californians and Seattleites are known for, I like the style of presentation and the careful attention to detail that is commonplace in England, and the New Yorker in me, likes the rough and tumble. I like managing people, I like turning around failing projects, and I like making decisions.Contact me directly through LinkedIn or at a••••••••@gmail.com
Experience
Scientific Associate Director Translational Research Cellular Therapy
Oct 2024 — Present
Lead the biomarker strategy for predictive, pharmacodynamic, and safety biomarkers across various phases of clinical development for CAR-T therapies in hematological malignancies.• Spearheaded the formation and management of the Liso-cel Follicular Lymphoma Correlative Analysis Group, organizing cross-functional teams across Translational Research, Clinical, Biostatistics, Bioinformatics, and Medical Affairs.• Drove the investigation of critical translational questions regarding minimal residual disease (MRD), CAR-T resistance mechanisms, and factors impacting CAR-T activity.• Led the oversight for the biomarker, pharmacodynamic, and safety testing sections of regulatory submissions, contributing to FDA and EMA approvals of Breyanzi (liso-cel) for follicular lymphoma and the successful FDA submission for marginal zone lymphoma.
Education
Stony Brook University | Cold Spring Harbor Laboratory
PhD
State University of New York College at Purchase
BA
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.